The TeliMET NSCLC-1 phase III trial, which will compare Teliso-V monotherapy versus docetaxel in advanced-stage non-squamous NSCLC patients with MET overexpression, is currently underway (Table 2). The gene discussed is MET; the disease is non-small cell lung carcinoma.